Glenmark's Ryaltris meets in Phase III for seasonal allergic rhinitis
Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) reported data from a Phase III trial in 1,180 patients with seasonal allergic rhinitis showing that twice-daily Ryaltris mometasone/olopatadine met the primary endpoint of improving average morning and evening patient-reported 12-hour reflective Total Nasal Symptom Score (TNSS) from baseline to day 14 vs. placebo (p<0.001).
Secondary endpoints in the double-blind, U.S. trial include the change from baseline in average morning and evening patient-reported 12-hour instantaneous TNSS, 12-hour reflective Total Ocular Symptom Score and Rhinoconjunctivitis Quality of Life Questionnaire score...
BCIQ Company Profiles
BCIQ Target Profiles